Serum sCD40L levels are increased in patients with Psoriatic Arthritis and are associated with clinical response to apremilast.

Serum sCD40L levels are increased in patients with Psoriatic Arthritis and are associated with clinical response to apremilast. Clin Exp Immunol. 2020 May 07;: Authors: Venerito V, Natuzzi D, Bizzoca R, Lacarpia N, Cacciapaglia F, Lopalco G, Iannone F Abstract The pathogenesis of Psoriatic Arthritis (PsA) involves several pathways, including the CD40/CD40L signaling which promotes the release of multiple cytokines. Transmembrane CD40L is also released as soluble form (sCD40L) and Phosphodiesterase 4- (PDE4) seems to be involved in its cleavage. We aimed to investigate whether apremilast, a PDE4 inhibitor, could modify circulating level of sCD40L in PsA patients, and the possible associations of these changes with clinical response. Consecutive PsA patients starting apremilast in routine clinical practice were prospectively observed. Disease Activity of Psoriatic Arthritis (DAPSA), Psoriasis Area Severity Index (PASI), Leeds Enthesitis Score (LEI), and serum samples were collected at baseline and at 6 months. Samples were run in a Bio-Plex ProTM plate for sCD40L. To investigate the association of sCD40L level with DAPSA based minor response, low disease activity (LDA) and/or remission at 6 months of treatment, multivariate logistic regression models with backward selection (p <0.05) were built. We studied 27 patients (16/27 women, 59.6%) with PsA and mean age (± SD) of 58.4 ± 10 years. A significant reduction of the mean values o...
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Tags: Clin Exp Immunol Source Type: research